Efficacy and safety of the Cav2.2 blocker Ziconotide in pain: a meta-analysis and systematic review

Chronic pain remains a significant clinical challenge, especially in refractory cases. Ziconotide, a selective Ca<sub>v</sub>2.2 channel blocker, offers an intrathecal approach, but concerns about its safety, potential biases, and impact on opioid consumption persist. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a systematic review and meta-analysis of 23 studies (1,531 participants) to evaluate the efficacy, safety, and secondary outcomes of Ziconotide. Key outcomes were pain intensity reduction, adverse events, and serious adverse events. As secondary outcomes, we assessed changes in opioid consumption. The risk of bias and the certainty of evidence were assessed using risk of bias 2 and Grading of Recommendations, Assessment, Development and Evaluation for randomized controlled trials, ROBINS-I and the Newcastle-Ottawa Scale for observational studies, and the Joanna Briggs Institute checklist for case reports. Publication bias was explored using funnel plot analysis. Ziconotide demonstrated significant pain reduction compared with placebo (mean difference: -22.54, 95% confidence interval [CI]: -36.70 to -8.38, <i>P</i> = 0.002), although heterogeneity was high. Adverse events were frequent (94.9% vs 76.9% in placebo; risk ratio 1.24, 95% CI: 1.09-1.41, <i>P</i> = 0.0008), with serious adverse events reported in 17.85% patients (risk ratio 2.63, 95% CI: 1.52-4.57, <i>P</i> = 0.0006). Secondary outcomes suggested potential reductions in opioid consumption in observational studies, with decreases ranging from 6.4% to 91.5%, though randomized trials showed inconsistent results. Certainty of the evidence was rated as low to moderate. Although Ziconotide shows promise as an intrathecal treatment for refractory pain, its frequent adverse effects, the availability of high-certainty evidence, and inconclusive impact on opioid consumption highlight the need for cautious use. This meta-analysis underscores the need for future research.

Authors

Institutions

Publication Details

Journal
PAIN Reports
Published
2025-11-14
DOI
https://doi.org/10.1097/pr9.0000000000001363
Primary Topic
Pain Management and Opioid Use
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of the Cav2.2 blocker Ziconotide in pain: a meta-analysis and systematic review

Xavier Gasull, F Sartori, Aida Castellanos, Javier Picañol et al.
PAIN Reports
Pain Management and Opioid Use
article

Efficacy and safety of the Cav2.2 blocker Ziconotide in pain: a meta-analysis and systematic review

Xavier Gasull, F Sartori, Aida Castellanos, Javier Picañol, David Soto
article en

Abstract

Chronic pain remains a significant clinical challenge, especially in refractory cases. Ziconotide, a selective Ca<sub>v</sub>2.2 channel blocker, offers an intrathecal approach, but concerns about its safety, potential biases, and impact on opioid consumption persist. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a systematic review and meta-analysis of 23 studies (1,531 participants) to evaluate the efficacy, safety, and secondary outcomes of Ziconotide. Key outcomes were pain intensity reduction, adverse events, and serious adverse events. As secondary outcomes, we assessed changes in opioid consumption. The risk of bias and the certainty of evidence were assessed using risk of bias 2 and Grading of Recommendations, Assessment, Development and Evaluation for randomized controlled trials, ROBINS-I and the Newcastle-Ottawa Scale for observational studies, and the Joanna Briggs Institute checklist for case reports. Publication bias was explored using funnel plot analysis. Ziconotide demonstrated significant pain reduction compared with placebo (mean difference: -22.54, 95% confidence interval [CI]: -36.70 to -8.38, <i>P</i> = 0.002), although heterogeneity was high. Adverse events were frequent (94.9% vs 76.9% in placebo; risk ratio 1.24, 95% CI: 1.09-1.41, <i>P</i> = 0.0008), with serious adverse events reported in 17.85% patients (risk ratio 2.63, 95% CI: 1.52-4.57, <i>P</i> = 0.0006). Secondary outcomes suggested potential reductions in opioid consumption in observational studies, with decreases ranging from 6.4% to 91.5%, though randomized trials showed inconsistent results. Certainty of the evidence was rated as low to moderate. Although Ziconotide shows promise as an intrathecal treatment for refractory pain, its frequent adverse effects, the availability of high-certainty evidence, and inconclusive impact on opioid consumption highlight the need for cautious use. This meta-analysis underscores the need for future research.

PAIN ReportsVol. 10(6)
Universitat Pompeu Fabra (ES), Institute for Research in Biomedicine (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Universitat Ramon Llull (ES)
Openalex Percentile: Top 46%
Pain Management and Opioid Use
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.